The 21 most recent market catalysts affecting $BHVN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 19, 2026
Corporate Catalyst
Bullish
Impact 85
Biohaven Reports Positive Phase 1 Clinical Data for BHV-1530
Biohaven reported encouraging Phase 1 clinical data for BHV-1530, an antibody-drug conjugate targeting FGFR3-altered tumors. The drug demonstrated a 60% partial response rate in ev…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 65
Biohaven Announces Progress Across Its Graves' Disease Program
Biohaven announced significant progress in its Graves' disease program, BHV-1300, with ongoing Phase 3 trials and positive Phase 1b data showing an 80% reduction in pathogenic auto…
Nov 3, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Biohaven at Overweight, Raises Price Target to $21
Morgan Stanley, a prominent investment bank, has maintained its 'Overweight' rating on Biohaven Ltd. (BHVN) and raised its price target from $19 to $21. This action indicates a str…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 55
Deutsche Bank Adjusts Biohaven Price Target to $23 From $26, Maintains Buy Rating
Deutsche Bank adjusted its price target for Biohaven Ltd. (BHVN) shares downward from $26 to $23, though it maintained a 'Buy' rating. This change occurred after the company's thir…
Oct 30, 2026
Corporate Catalyst
Bearish
Impact 55
Biohaven Ltd. Analyst Price Target Adjusted to $25
Biohaven Ltd. has seen its average 12-month analyst price target adjusted to $25, reflecting a 52% potential upside from the previous day's closing price. This adjustment, while no…
Oct 29, 2026
Corporate Catalyst
Bearish
Impact 85
Biohaven Reports Q3 2026 Financial Results and Regulatory Updates
Biohaven's Q3 2026 results showed a smaller-than-expected loss, which is a positive. The FDA's acceptance of the Vyglxia resubmission for SCA, along with a user fee goal date and a…
Oct 25, 2026
Corporate Catalyst
Neutral
Impact 55
Baird Maintains Buy Rating on Biohaven, Adjusts Price Target
Baird analyst Brian Skorney maintained a 'Buy' rating on Biohaven Ltd. (BHVN), indicating continued confidence in the company's long-term prospects. However, the price target was l…
Oct 23, 2026
Corporate Catalyst
Neutral
Impact 65
Analysts Adjust Biohaven Price Targets Following FDA News
The filing indicates that Biohaven has received positive news regarding its drug Vyglxia, with the FDA accepting its resubmitted New Drug Application (NDA). This regulatory progres…
Oct 23, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Raises Price Target on Biohaven to $22 From $19
RBC Capital Markets raised its price target on Biohaven Ltd. from $19 to $22, while keeping a 'Sector Perform' rating. This positive adjustment stems directly from the FDA's accept…
Oct 22, 2026
Corporate Catalyst
Bullish
Impact 75
Biohaven Shares Rise After FDA Accepts Vyglxia Resubmission for Review
Biohaven received a Complete Response Letter in November 2025 for Vyglxia, indicating the FDA was not satisfied with the initial application. The acceptance of the resubmission, wh…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 75
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven (BHVN) has announced a strategic licensing and collaboration agreement with Ono Pharmaceutical, granting Ono exclusive rights to develop and commercialize Biohaven's MoDE …
Sep 28, 2026
Corporate Catalyst
Neutral
Impact 75
Biohaven To Present Data On BHV-1530, FGFR3-Directed ADC Using Topoisomerase I Payload, At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Biohaven announced that its investigational cancer drug, BHV-1530, an FGFR3-directed ADC, has been selected for an oral presentation at a prestigious oncology symposium (ENA 2026).…
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 85
Biohaven shares are trading lower after the company announced the FDA ordered a pause on new enrollment in BHV-7000 program and issued a partial clinical hold on September 4, pending additional nonclinical metabolite data.
This FDA clinical hold is a major negative catalyst for Biohaven, directly impacting its lead pipeline candidate, BHV-7000. The pause in new enrollment and partial hold signal regu…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026
Biohaven received a partial clinical hold from the FDA, pausing new patient enrollment for its Kv7 ion channel program (BHV-7000) due to insufficient information regarding a specif…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 65
RBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19
RBC Capital's downgrade of Biohaven (BHVN) from Outperform to Sector Perform, coupled with a price target reduction from $23 to $19, indicates a less optimistic view from the analy…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 95
Why Is Biohaven Stock Soaring Wednesday?
Biohaven (BHVN) experienced a significant positive catalyst due to two major announcements. First, a global licensing agreement with SK Biopharmaceuticals for its Kv7 platform, inc…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 92
Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront
Biohaven has entered into a licensing agreement with SK Biopharmaceuticals for its Kv7 platform and the epilepsy candidate opakalim. This is a major positive catalyst for Biohaven …
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23
RBC Capital analyst Leonid Timashev maintained an 'Outperform' rating on Biohaven (BHVN) and raised the price target from $22 to $23. This action signals continued confidence from …
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Biohaven Q2 Adj. EPS $(0.78) Misses $(0.73) Estimate
Biohaven announced its Q2 adjusted EPS of $(0.78), which fell short of the analyst consensus estimate of $(0.73). This 6.85% miss indicates that the company's financial performance…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
Biohaven And Yale University Announce Federal Jury Verdict In Their Favor In Trade Secret Misappropriation And Breach Of Contract Litigation Against Avilar Therapeutics And RA Capital
A federal jury found Avilar Therapeutics and RA Capital liable for willfully and maliciously misappropriating a Yale trade secret (the MODA platform) and for RA Capital breaching a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.